Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for BridgeBio Pharma (BBIO) over the last 7 years, with Q3 2025 value amounting to $643.0 million.

  • BridgeBio Pharma's Cash & Equivalents rose 14141.68% to $643.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $643.0 million, marking a year-over-year increase of 14141.68%. This contributed to the annual value of $681.1 million for FY2024, which is 8117.52% up from last year.
  • According to the latest figures from Q3 2025, BridgeBio Pharma's Cash & Equivalents is $643.0 million, which was up 14141.68% from $749.0 million recorded in Q2 2025.
  • BridgeBio Pharma's Cash & Equivalents' 5-year high stood at $749.0 million during Q2 2025, with a 5-year trough of $180.3 million in Q3 2021.
  • For the 5-year period, BridgeBio Pharma's Cash & Equivalents averaged around $446.3 million, with its median value being $408.0 million (2024).
  • As far as peak fluctuations go, BridgeBio Pharma's Cash & Equivalents crashed by 5085.47% in 2021, and later soared by 16794.73% in 2022.
  • BridgeBio Pharma's Cash & Equivalents (Quarter) stood at $393.8 million in 2021, then fell by 4.34% to $376.7 million in 2022, then fell by 0.2% to $375.9 million in 2023, then soared by 81.18% to $681.1 million in 2024, then decreased by 5.6% to $643.0 million in 2025.
  • Its Cash & Equivalents stands at $643.0 million for Q3 2025, versus $749.0 million for Q2 2025 and $540.6 million for Q1 2025.